医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

WallStAnalyst.com: Generic Drug Makers Focus on Expansion into Biosimilars; US Stocks Edge Higher With Positive Consumer News

2014年02月10日 PM10:25
このエントリーをはてなブックマークに追加


 

NEW YORK

Wall St. Analyst (www.wallstanalyst.com) has announced its comprehensive market summary that analyzes the most relevant news, events, and economic releases. This edition of the newsletter provides an insight into why the US stock market witnessed a rebound during the week ended 7th February 2014 after positive news relating to consumer credits released by the Fed. The newsletter also throws the spotlight on how giant generic drug makers are focusing their R&D efforts and investments on biosimilars as part of their growth strategy to effectively compete with smaller companies in the emerging nations.

Major Stock Indices Rise After the Fed’s Consumer Credit Report
The Consumer Credit report for December released by the Federal Reserve shows that consumer credit has increased. This brings into sharp focus the debate as to whether the recovery of the US economy is for real or just a blip on an otherwise dull outlook being portrayed by other key economic indicators. As a result, the major stock indices rose during the week, recording their first gain over the past four weeks, after being battered by weak labor market data as well as harsh weather conditions. More details about the consumer sentiments in the US economy is available at

http://wallstanalyst.com/research-desk/market-monitoring/1209-market-monitoring-week-ended-7-february-2014

Major Drug Makers Eye a Slice of Booming Biosimilars Market
WallStAnalyst.com analyses how the major generics drug makers are focusing on expansion into the biosimilars market, which is seen to have huge potential over the next few years. This is mainly because many blockbuster drugs are expected to go off patent during the second half of 2014. Biosimilars are currently witnessing high growth as they are relatively cheaper to make and just as effective as their biopharmaceutical counterparts. However, drug companies will have to tackle EU pricing pressure and compete with popular branded products to gain a firm foothold in this market. More details about growth prospects of the biosimilars market is available at

http://wallstanalyst.com/blog/entry/giant-generic-drug-maker-teva-gets-new-seasoned-captain-on-board

Focus Concepts, Sectors, and Companies
Verisign
LinkedIn
Cigna Corp.
Noble Energy
Netflix
Expedia
TripAdvisor Inc.
Priceline.com Inc.
Flir Systems Inc.
Wyndham Worldwide
Apollo Global Management
Moody’s Corp.
Beam Inc.
Western Union
LabCorp
Thomson Reuters

For more information visit www.wallstanalyst.com

CONTACT

Wall Street Analyst
Ms. Vani Rao, Chief Editor
+1 347-394-0245
press@wallstanalyst.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent